|
Emerging Treatment Options for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Emerging Treatment Strategies for High-Risk Myelodysplastic Syndromes |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Evolving Treatment Options for Low-Risk Myelodysplastic Syndromes |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Evolving Treatment Options for Relapsed/Refractory Follicular Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Evolving Treatment Strategies for Acute Myeloid Leukemia |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Fertility Preservation in Hematologic Malignancies: Navigating Complex Choices |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Incorporating TKIs in the Treatment of Myelofibrosis |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Integrating New Therapies for the Treatment of Chronic Phase Chronic Myeloid Leukemia |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Management of High-Risk Acute Promyelocytic Leukemia in the Community Setting |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma |
1.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Monitoring Toxicities in the Ambulatory Setting |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
NCCN 2025 Annual Congress: Hematologic Malignancies™ |
14.50 |
10/11/2025 - 11:30am to 05/31/2026 - 11:59pm |
|
NCCN 2026 Annual Conference: In-Person Attendance |
20.25 |
03/29/2026 - 10:30am to 06/30/2026 - 11:59pm |
|
NCCN 2026 Annual Conference: Virtual Attendance |
16.25 |
03/29/2026 - 10:30am to 06/30/2026 - 11:59pm |
|
NCCN 2026 Oncology Fellows Program: New Horizons in Quality Cancer Care |
5.50 |
04/20/2026 - 12:00am to 07/01/2026 - 12:00am |
Facebook
X
LinkedIn
Forward